{"filings":[{"id":94404,"accession_number":"0001193125-26-211904","cik":1650648,"company_name":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"4DMT Q1 net loss $68.8M; cash $458M; 4D-150 Phase 3 enrollment complete","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $458M as of Mar 31, 2026, down from $514M; expected to fund ops into H2 2028.","Net loss $68.8M vs $48.0M YoY; R&D expenses rose to $65.0M on Phase 3 trial execution.","4D-150 wet AMD Phase 3 (4FRONT-1) randomization complete (N=523); topline data H1 2027.","PRISM Phase 2b 2-year data for wet AMD expected at a conference Q3 2026; SPECTRA DME 2-year data H2 2026.","4D-710 (CF) AEROW trial update expected H2 2026; 4D-175 (GA) evaluating strategic funding."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":3047000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":469440770.1536724,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106778,"accession_number":"0001193125-26-131739","cik":1650648,"company_name":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"4DMT appoints CFO Kristian Humer as Principal Accounting Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment effective March 25, 2026; Humer succeeds Ashoo Gupta.","Humer continues as CFO and Principal Financial Officer (role since Nov 2025).","Prior roles include CFO at Foghorn Therapeutics (Apr 2024–Nov 2025) and Viridian Therapeutics.","Gupta remains Vice President, Finance and Controller of the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":469440770.1536724,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106777,"accession_number":"0001193125-26-113949","cik":1650648,"company_name":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","form_type":"8-K","filed_at":"2026-03-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"4DMT FY2025 net loss $140M; cash $514M; 4D-150 Phase 3 enrollment completed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $140M in FY2025 versus $161M in FY2024; R&D expenses $196M (up from $141M).","Cash, equivalents and securities $514M; expected to fund operations into H2 2028.","4D-150 4FRONT-1 Phase 3 wet AMD enrollment completed; topline data expected H1 2027.","Otsuka partnership for 4D-150 in Asia-Pacific provided $85M upfront; up to $336M milestones plus royalties.","Leadership additions: new CFO Kristian Humer, CMO Julie Clark, CTO Katy Barglow, Board member Glenn Sblendorio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":469440770.1536724,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106776,"accession_number":"0001193125-26-022559","cik":1650648,"company_name":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","form_type":"8-K","filed_at":"2026-01-26T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"4D Molecular Therapeutics exchanges 6.6M shares for pre-funded warrants with RA Capital and BVF","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["RA Capital exchanged 4,850,000 shares for a warrant to acquire 4,850,000 shares.","BVF exchanged 1,750,000 shares for a warrant to acquire 1,750,000 shares.","Post-exchange shares outstanding as of Jan 23, 2026: 51,007,874; warrants exercisable for 16,935,665 total shares.","Warrants have $0.0001 exercise price, no expiration, and 4.99%/9.99% beneficial ownership blocker.","Issued in reliance on Section 3(a)(9) exemption from registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":469440770.1536724,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106775,"accession_number":"0001193125-26-005470","cik":1650648,"company_name":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["2.02","5.02"],"status":"ready","headline":"4D Molecular Therapeutics reports ~$514M cash; President/COO resigns, CEO assumes President role; new director appointed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Fariborz Kamal resigned as President/COO effective Dec 31, 2025; transitions to part-time Chief Technical Advisor.","CEO David Kirn appointed President as of Jan 1, 2026, in addition to CEO role.","Glenn Sblendorio appointed to Board as Class I director effective Jan 5, 2026, serving on Compensation and Science/Technology Committees.","Preliminary cash, cash equivalents and marketable securities ~$514M as of Dec 31, 2025 (unaudited, subject to closing).","Mr. Sblendorio received initial option for 45,000 shares at $7.30 exercise price; annual cash retainer of $40,000 plus committee fees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":469440770.1536724,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123084,"accession_number":"0001193125-25-314167","cik":1650648,"company_name":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"4D Molecular Therapeutics increases wet AMD trial enrollment to 480 patients for global regulatory submissions","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Target enrollment for 4FRONT-1 and 4FRONT-2 Phase 3 trials raised from 400 to 480 patients each.","Amendments aim for ~90% power with ~4-letter noninferiority margin for non-FDA agencies (e.g., PMDA, EMA).","No impact on guided enrollment completion or financial runway into H2 2028; 4FRONT-1 topline expected H1 2027.","Asia-Pacific regulatory submissions supported by Otsuka partnership, leveraging global commercial opportunity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":469440770.1536724,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123083,"accession_number":"0001193125-25-283861","cik":1650648,"company_name":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"4D Molecular Therapeutics appoints Kristian Humer as CFO effective Nov 17, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kristian Humer, formerly CFO at Foghorn Therapeutics and Viridian Therapeutics, joins as CFO and Principal Financial Officer.","Compensation includes $520K base salary, 40% target bonus, option for 480K shares, and $100K sign-on bonus paid in two installments.","Severance: 9 months base salary + COBRA if terminated w/o cause or for good reason; 12 months + COBRA plus full equity acceleration if within 12 months of a change in control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":469440770.1536724,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123082,"accession_number":"0001193125-25-273340","cik":1650648,"company_name":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"4DMT reports Q3 net loss $56.9M, enters Otsuka partnership for 4D-150 APAC rights for $85M upfront","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $56.9M in Q3 2025 vs $43.8M in Q3 2024; R&D expenses $49.4M (up from $38.5M).","Otsuka partnership: $85M upfront + $50M cost sharing; up to $336M milestones + royalties. 4DMT retains ex-APAC rights.","Cash $372M at Sept 30; + Otsuka payments + $93M equity raise extends runway into H2 2028.","4FRONT Phase 3 enrollment: >200 patients randomized in 4FRONT-1; topline data H1 2027. 4FRONT-2 on track.","Positive long-term PRISM (wet AMD) and SPECTRA (DME) data; 4D-150 well tolerated with durable benefit."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":119000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":469440770.1536724,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123081,"accession_number":"0001193125-25-272286","cik":1650648,"company_name":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"4D Molecular Therapeutics raises ~$93.3M net in public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 8,385,809 shares at $10.51/share and 1,128,949 pre-funded warrants at $10.5099 each.","Net proceeds approximately $93.3M after underwriting discounts and estimated expenses.","Offering closed on November 7, 2025; insiders subject to lock-up until January 6, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":469440770.1536724,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123080,"accession_number":"0001193125-25-267934","cik":1650648,"company_name":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"4D Molecular announces positive interim 1.5-3.5 year data for 4D-150 in wet AMD; 79-92% injection reduction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, equivalents and marketable securities $372.2M as of Sept 30, 2025.","Phase 2b recently diagnosed subgroup (Phase 3 comparable): 92% reduction in mean supplemental injections vs aflibercept at 1.5 years.","Phase 2b broad cohort: 82% reduction; Phase 1/2a severe recalcitrant: 79% reduction at 2 years.","Safety: 2.8% (2/71) mild transient IOI within 28 weeks; no new IOI after 28 weeks; no hypotony, endophthalmitis, vasculitis.","Consistent dose response favoring Phase 3 dose (3E10 vg/eye) over lower dose across all cohorts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":469440770.1536724,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123079,"accession_number":"0001193125-25-259302","cik":1650648,"company_name":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","form_type":"8-K","filed_at":"2025-10-31T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"4D Molecular Therapeutics (FDMT) signs $85M upfront license deal with Otsuka for 4D-150 in APAC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront cash payment of $85M from Otsuka; additional cost sharing of at least $50M over next three years.","Potential regulatory and commercial milestones up to $335.5M, plus tiered double-digit royalties on net sales in APAC.","Otsuka gains exclusive rights to develop and commercialize 4D-150 for wet AMD and DME in Japan, China, Australia, and other APAC markets.","Phase 3 study 4FRONT-1 enrollment exceeds expectations: over 200 patients randomized as of Oct 30, 2025.","FDMT retains full rights outside APAC, including US, Latin America, and Europe."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":469440770.1536724,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123078,"accession_number":"0001193125-25-228289","cik":1650648,"company_name":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","form_type":"8-K","filed_at":"2025-10-02T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"4D Molecular Therapeutics appoints Ashoo Gupta as Principal Financial Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ashoo Gupta appointed Principal Financial Officer and Principal Accounting Officer effective September 30, 2025.","Mr. Gupta previously served as VP Finance & Controller at 4D since June 2024.","Prior roles include VP Finance and Corporate Controller at Kyverna Therapeutics and Executive Director of Accounting at Myovant Sciences.","Board amended and restated bylaws to update advance notice procedures for business and director nominations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":469440770.1536724,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139775,"accession_number":"0000950170-25-106243","cik":1650648,"company_name":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"4DMT Q2 net loss $54.7M; accelerates 4D-150 Phase 3 wet AMD data to H1 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $417M (down from $505M Dec 2024); funds into 2028; workforce cut ~25% saves ~$15M/yr.","Net loss $54.7M vs $35.0M Q2 2024; R&D spend $48.0M (+50% YoY) on Phase 3 startup.","4FRONT-1 wet AMD Phase 3 topline data accelerated to H1 2027; 4FRONT-2 initiated ahead of schedule.","DME SPECTRA 60-wk: Phase 3 dose 78% fewer injections vs on-label aflibercept; FDA/EMA align on single-study approval.","RMAT designation for 4D-150 in DME; 4D-710 cystic fibrosis cohort enrollment complete, data Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":29000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":469440770.1536724,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139774,"accession_number":"0000950170-25-092964","cik":1650648,"company_name":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","form_type":"8-K","filed_at":"2025-07-02T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"4D Molecular Therapeutics reduces workforce 25%, accelerates wet AMD data to H1 2027; CFO resigns","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CFO Uneek Mehra resigns effective July 15; remains principal financial officer through September 2025 and Q2 filing.","Phase 3 4FRONT-1 wet AMD trial topline data accelerated to H1 2027 (from H2 2027); 4FRONT-2 started in June 2025.","Workforce reduction of ~25% of current and planned roles in July 2025, primarily early-stage R&D and support functions.","Expected $3M in severance costs in Q3 2025; annual cash compensation savings of ~$15M.","Cash, equivalents and marketable securities of $458M as of March 31, 2025; runway into 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":469440770.1536724,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157341,"accession_number":"0000950170-25-088482","cik":1650648,"company_name":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"4D Molecular Therapeutics annual meeting results: all four proposals approved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders elected Jacob Chacko, Susannah Gray, and Charles Theuer as Class II directors.","Ratified PricewaterhouseCoopers as independent auditor for FY2025.","Say-on-pay proposal approved (31.8M for, 394k against, 35k abstain, 6.2M broker non-votes).","Advisory vote on future say-on-pay frequency: one year chosen; company will hold annual votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":469440770.1536724,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157340,"accession_number":"0000950170-25-067013","cik":1650648,"company_name":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"4DMT Q1 net loss $48M; initiates 4D-150 Phase 3 in wet AMD; cash runway to 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $48.0M vs $32.4M YoY; R&D expenses $40.7M (+46% YoY) due to Phase 3 startup.","Cash $458M (down from $505M Dec 2024); expected to fund operations into 2028.","First patients enrolled in 4D-150 Phase 3 (4FRONT-1) in wet AMD; 4FRONT-2 starts Q3 2025; topline H2 2027.","FDA RMAT designation for 4D-150 in DME; FDA aligned on single Phase 3 trial for BLA.","Pipeline focused on 4D-150 and 4D-710; paused/terminated 4D-175, 4D-725, 4D-310, 4D-110, 4D-125."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":14000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":469440770.1536724,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175717,"accession_number":"0000950170-25-030020","cik":1650648,"company_name":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","form_type":"8-K","filed_at":"2025-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"4DMT reports FY2024 net loss of $160.9M; cash $505M; Phase 3 programs on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $160.9M in 2024 vs $100.8M in 2023; R&D expenses $141.3M (up 46% YoY).","Cash, cash equivalents and marketable securities of $505M as of Dec 31, 2024, funding operations into 2028.","Phase 3 4FRONT trials for 4D-150 in wet AMD to initiate March 2025 and Q3 2025; topline data expected H2 2027.","FDA aligned that a single Phase 3 trial is acceptable for BLA submission of 4D-150 in DME.","Pipeline focused on 4D-150 (wet AMD, DME) and 4D-710 (CF); paused other programs and terminated early-stage rare disease trials."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.98,"consensus_revenue_estimate":null,"consensus_revenue_actual":37000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":469440770.1536724,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175716,"accession_number":"0000950170-25-016708","cik":1650648,"company_name":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"4D Molecular reports positive 52-week Phase 2b data for wet AMD therapy 4D-150","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2b (n=30): 83% reduction in supplemental aflibercept injections (0.97 mean vs 6.0 on-label); 57% injection-free over 52 weeks.","Recently diagnosed subgroup (n=15): 94% reduction (0.33 mean injections); 80% injection-free.","Safety: well tolerated up to 3 years; 2.8% (2/71) 4D-150-related 1+ IOI; no hypotony, endophthalmitis, or vasculitis.","Durable aflibercept expression up to 2 years; aqueous humor levels consistently within projected therapeutic range.","Phase 3 trials 4FRONT-1 (Q1 2025) and 4FRONT-2 (Q3 2025) to initiate; topline 52-week data expected H2 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":469440770.1536724,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175715,"accession_number":"0000950170-25-003832","cik":1650648,"company_name":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"4D Molecular reports positive 32-week DME data; FDA aligns on single Phase 3; cash runway into 2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, equivalents, securities $506M as of Dec 31; cash runway extended to 2028.","SPECTRA Part 1 (DME): 4D-150 well tolerated, no intraocular inflammation; high dose +8.4 letters BCVA, -194 µm CST; mean 0.6 supplemental injections vs 4.0 for aflibercept.","FDA: single Phase 3 trial (300-400 patients) acceptable for BLA for 4D-150 in DME; SPECTRA Part 2 no longer needed.","Pipeline refocus: core 4D-150 (wet AMD/DME) and 4D-710 (CF); discontinue 4D-110 and 4D-125; reduce investment in 4D-175/725/310 pending partnerships.","Phase 3 4FRONT trials for wet AMD start Q1 and Q3 2025; topline data expected H2 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":469440770.1536724,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192653,"accession_number":"0000950170-24-135381","cik":1650648,"company_name":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","form_type":"8-K","filed_at":"2024-12-11T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"RA Capital exchanges 535k FDMT shares for pre-funded warrant at $0.0001 strike","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["RA Capital Healthcare Fund exchanged 535,000 shares of common stock for a pre-funded warrant to purchase 535,000 shares at $0.0001 per share.","Warrant is immediately exercisable, never expires, and includes a 9.99% beneficial ownership blocker.","Issued under Section 3(a)(9) exemption; no new cash proceeds to the company.","Warrant terms adjust for stock splits, dividends, and asset distributions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":469440770.1536724,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192652,"accession_number":"0000950170-24-126346","cik":1650648,"company_name":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"4DMT reports Q3 2024 net loss $43.8M, cash $551M; 4D-150 Phase 3 on track for Q1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $43.8M (vs $10.3M Q3 2023); R&D expense $38.5M (vs $25.1M) on trial progression.","Cash & equivalents $551M; expected to fund operations at least into H1 2027.","Positive 4D-150 interim data: 83% injection reduction in severe population; 70-87% 52-week injection-free rate.","4FRONT-1 Phase 3 trial for 4D-150 in wet AMD initiation expected Q1 2025.","New senior hires: Dhaval Desai (CDO), Christopher Simms (CCO), Carlos Quezada-Ruiz (SVP Ophthalmology)."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":36000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":469440770.1536724,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209107,"accession_number":"0001193125-24-221375","cik":1650648,"company_name":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","form_type":"8-K","filed_at":"2024-09-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"4D-150 shows up to 98% injection reduction in wet AMD; Phase 3 4FRONT expected Q1 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2b Broad (n=30): 89% annualized injection reduction, 80% with 0 or 1 injection, 70% injection-free at 52 weeks.","Phase 2b Recently Diagnosed (n=15): 98% injection reduction, 100% with 0 or 1 injection, 87% injection-free.","Safety: 2.8% rate of 4D-150-related IOI (2 of 71); no hypotony, endophthalmitis, or vasculitis observed.","Planned Phase 3 4FRONT-1 (N=500) to start Q1 2025; primary endpoint noninferiority BCVA vs aflibercept; RMAT and PRIME designations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":469440770.1536724,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209106,"accession_number":"0000950170-24-093992","cik":1650648,"company_name":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"4DMT reports Q2 net loss $35M, cash $578M; positive 4D-150 interim data; FDA lifts clinical hold on 4D-310","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $578M as of June 30, 2024; expected to fund operations into H1 2027.","Q2 net loss $35.0M vs $29.6M YoY; R&D expenses rose to $31.9M from $23.6M.","Phase 2 PRISM 4D-150 in wet AMD: 89% reduction in annualized anti-VEGF injections; 77% injection-free at 24 weeks with 3E10 vg/eye dose.","FDA removed clinical hold on Phase 1/2 INGLAXA trial for 4D-310 in Fabry disease cardiomyopathy; enrollment to resume H2 2024.","Senior leadership added: Dhaval Desai (CDO), Christopher Simms (CCO), Carlos Quezada-Ruiz (SVP Ophth); Ophthalmology Advisory Board formed."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":33000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":469440770.1536724,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209105,"accession_number":"0001193125-24-182544","cik":1650648,"company_name":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","form_type":"8-K","filed_at":"2024-07-23T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"4D Molecular Therapeutics to present interim 4D-150 wet AMD data at September 2024 medical conference","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Interim data from Phase 1/2 PRISM trial (Dose Expansion, Phase 2 Dose Expansion, Phase 2 Population Expansion cohorts) expected at September 2024 medical conference.","Specific forum and date to be disclosed with Q2 2024 financial results in August 2024.","52-week landmark analyses for Dose Expansion and Population Expansion cohorts on track for February 2025 as previously disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":469440770.1536724,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209104,"accession_number":"0001193125-24-179950","cik":1650648,"company_name":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","form_type":"8-K","filed_at":"2024-07-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"4D-150 Phase 2 interim data shows 89% injection rate reduction, 77% injection-free at 24 weeks in wet AMD","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Planned Phase 3 dose (3E10 vg/eye): 89% reduction in mean annualized injection rate; 77% injection-free at 24 weeks.","No 4D-150-related SAEs, no hypotony, retinal vasculitis, or choroidal effusions observed in any patient across trials (n=139).","BCVA improved by +4.2 letters from baseline at 3E10 dose; injection-free patients saw +4.7 letters; dose response favored higher dose.","Phase 1 patients (n=3) treated at 3E10 remained injection-free through ~2-2.5 years; BCVA and CST stable.","Expects to announce Phase 3 trial design in Sep 2024, initiate in Q1 2025; 52-week data and DME data due in H2 2024/early 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":469440770.1536724,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226965,"accession_number":"0001193125-24-157521","cik":1650648,"company_name":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"4D Molecular Therapeutics enters $250M ATM equity distribution agreement with Leerink Partners","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company enters Sales Agreement to sell up to $250M common stock via at-the-market offering through Leerink Partners.","Agent compensation up to 3.0% of gross proceeds; sales made on Nasdaq via Rule 415(a)(4).","Offering registered under existing S-3 filed Feb 2024; prospectus supplement filed June 7, 2024.","No minimum sales obligation; company may terminate at any time upon prior notice.","Proceeds for general corporate purposes; no escrow arrangement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":469440770.1536724,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226964,"accession_number":"0001193125-24-147093","cik":1650648,"company_name":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"4D Molecular Therapeutics stockholders elect David Kirn as Class I director and ratify PwC as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["David Kirn, M.D. elected as Class I director with 35,630,613 votes for, 7,849,441 withheld, and 1,574,659 broker non-votes.","Ratification of PricewaterhouseCoopers LLP as independent auditor for FY2024: 45,032,000 for, 21,052 against, 1,661 abstain.","Annual Meeting held on May 21, 2024; 45,054,713 of 51,157,472 outstanding shares voted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":469440770.1536724,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226963,"accession_number":"0000950170-24-057035","cik":1650648,"company_name":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"4DMT Q1 2024 net loss $32.4M; advances 4D-150 toward Phase 3 for wet AMD","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $32.4M in Q1 2024 vs $28.7M in Q1 2023.","Cash $589M after $337M gross proceeds from upsized follow-on; runway into H1 2027.","4D-150 wet AMD: 89% injection burden reduction, 84% patients with 0-1 injections at 24 wks; Phase 3 start Q1 2025.","Upcoming: 4D-150 broader wet AMD data at ASRS July 2024; 4D-710 CF interim data at ECFS June 2024.","R&D expenses $27.9M, G&A $10.3M; both up YoY driven by clinical trial progression and headcount."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":28000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":469440770.1536724,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245906,"accession_number":"0000950170-24-023088","cik":1650648,"company_name":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"4DMT reports FY2023 net loss $100.8M; positive 4D-150 wet AMD data, Phase 3 plan Q1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $100.8M in 2023; cash $299M at Dec 2023; Feb 2024 offering $281M net; runway into H1 2027.","4D-150 interim data in wet AMD: favorable safety, no significant inflammation; 24-week data reduced treatment burden vs aflibercept.","Phase 3 trial for 4D-150 in wet AMD expected to start Q1 2025; FDA RMAT and EMA PRIME designations.","Pipeline progress: 4D-710 CF positive interim data; 4D-310 Fabry cardiac improvements; IND for 4D-175 GA expected Q2 2024.","Strategic partnerships: Astellas (up to $942.5M milestones) for ophthalmic vectors; Arbor for CNS gene editing."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":20723000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":469440770.1536724,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}